Apitegromab - Scholar Rock
Alternative Names: SRK-015Latest Information Update: 01 Jul 2025
At a glance
- Originator Scholar Rock
- Class Monoclonal antibodies; Obesity therapies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Spinal muscular atrophy
- Phase II Obesity
- No development reported Muscular atrophy; Spinal cord injuries
Most Recent Events
- 18 Jun 2025 Efficacy and adverse events data from a phase-II EMBRAZE trial in Obesity (Adjunctive treatment) released by Scholar Rock
- 14 May 2025 Scholar Rock plans to initiate launch Apitegromab for Spinal muscular atrophy in Europe in 2026
- 28 Mar 2025 Preregistration for Spinal muscular atrophy (In adolescents, In children, In adults) in European Union (IV)